Purpose: To assess the impact of fenfluramine (FFA) on the expected mortality incidence, including sudden unexpected death in epilepsy (SUDEP), in persons with Dravet syndrome (DS).
Methods: In this pooled analysis, total time of exposure for persons with DS who were treated with FFA in phase 3 clinical trials, in United States and European Early Access Programs, and in two long-term open-label observational studies in Belgium was calculated. Literature was searched for reports of SUDEP mortality in DS, which were utilized as a comparison. Mortality rates were expressed per 1000 person-years.
Results: A total of 732 persons with DS were treated with FFA, representing a total of 1185.3 person-years of exposure. Three deaths occurred, all in the phase 3 program: one during placebo treatment (probable SUDEP) and two during treatment with FFA (one probable SUDEP and one definite SUDEP). The all-cause and SUDEP mortality rates during treatment with FFA was 1.7 per 1000 person-years (95% CI, 0.4 to 6.7), a value lower than the all-cause estimate of 15.8 per 1000 person-years (95% CI, 9.9 to 25.4) and SUDEP estimate of 9.3 (95% CI, 5.0 to 17.3) reported by Cooper et al. (Epilepsy Res 2016;128:43-7) for persons with DS receiving standard-of-care.
Conclusion: All-cause and SUDEP mortality rates in DS patients treated with FFA were substantially lower than in literature reports. Further studies are warranted to confirm that FFA reduces SUDEP risk in DS patients and to better understand the potential mechanism(s) by which FFA lowers SUDEP risk.
Clinical Trial Registration: NCT02926898, NCT02682927, NCT02826863, NCT02823145, NCT03780127.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.seizure.2021.10.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sex-specific differences in mortality and neurocardiac interactions in the Kv1.1 knockout mouse model of sudden unexpected death in epilepsy (SUDEP).
J Physiol
January 2025
Department of Biological Sciences, Southern Methodist University, Dallas, TX, USA.
Sudden unexpected death in epilepsy (SUDEP) is a devastating complication of epilepsy with possible sex-specific risk factors, although the exact relationship between sex and SUDEP remains unclear. To investigate this, we studied Kcna1 knockout (Kcna1) mice, which lack voltage-gated Kv1.1 channel subunits and are widely used as a SUDEP model that mirrors key features in humans.
View Article and Find Full Text PDFThe effect of epilepsy surgery on tonic-clonic seizures.
Epilepsia
January 2025
Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Objective: Epilepsy surgery outcomes tend to be judged by the percentage in seizure reduction without considering the effect on specific seizure types, particularly tonic-clonic seizures, which produce the greatest morbidity and mortality. We assess how often focal to bilateral tonic-clonic seizures (BTCS) stop and how often they appear de novo after epilepsy surgery.
Methods: Analysis of a prospectively maintained epilepsy surgery database between 1986 and 2022 that characterizes the burden of BTCS after resective epilepsy surgery.
Early life stress influences epilepsy outcomes in mice.
Epilepsy Behav
December 2024
Tufts University School of Medicine, Neuroscience Department, Boston, MA, USA. Electronic address:
Article Synopsis
- Stress is a significant trigger for seizures and can worsen epilepsy outcomes, increasing psychiatric and cognitive issues, as well as the risk of sudden unexpected death in epilepsy (SUDEP).
- The hypothalamic-pituitary-adrenal (HPA) axis responds to stress, and its dysfunction has been shown to correlate with higher seizure frequency and behavioral problems in animal models.
- Early life stress (ELS), through a maternal separation model, alters the HPA axis and affects seizure susceptibility, with sex-dependent differences observed, particularly showing that females are more impacted by ELS in terms of epilepsy outcomes and mortality risk.
Community-Sourced Reporting of Mortalities in Angelman Syndrome (1979-2022).
Am J Med Genet A
December 2024
COMBINEDBrain, Brentwood, Tennessee, USA.
Article Synopsis
- Angelman syndrome (AS) is a rare genetic disorder impacting neurodevelopment, with an estimated prevalence of 1 in 20,000, but lacks comprehensive data on life expectancy and death rates due to a lack of diagnostic codes until 2018.
- A social media initiative by AS caregivers gathered data on 220 deaths, revealing respiratory illness as the leading cause, followed by accidents and seizures, with sudden unexpected death in sleep (SUDS) also being a notable concern.
- The study found that 91% of individuals with AS have epilepsy, suggesting that some SUDS cases could relate to sudden unexpected deaths in epilepsy (SUDEP), and highlights the need for more research despite limitations
Epilepsy and Cardiac Arrhythmias: A State-of-the-Art Review.
JACC Clin Electrophysiol
November 2024
Department of Cardiology, St Vincent's Hospital Melbourne, Fitzroy, VIC, Australia; Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Fitzroy, VIC, Australia; HEART Lab, St Vincent's Institute of Medical Research, Fitzroy, VIC, Australia; HEART Lab, Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia. Electronic address: https://twitter.com/pretzeldr.
Epilepsy is an important cause of disability and mortality worldwide. It can be frequently misdiagnosed, and detailed history and relevant investigations are needed to differentiate epilepsy from syncope. Electroencephalogram is a key noninvasive assessment of neurological function, and the diagnostic yield is increased when performed for an extended period in the ambulatory setting with concurrent electrocardiogram and video monitoring.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!